Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0598853 (forgetting)
 3,232 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a retrospective study the case histories of 70 users of Depo-Provera (containing depo medroxyprogesterone acetate) were reviewed during April-June 1987 at the Family Planning Association of Victoria's Richmond Clinic in Australia to ascertain their socioeconomic status, obstetric and contraceptive history, and side effects of Depo-Provera use. 47 (67%) were employed; 20 (29%) were health care card holders (8 were unemployed and 6 were supporting mothers); 2 were wards of state referred from adolescent institutions; and 3 women (4%) had intellectual disability. 37 (53%) had been pregnant with the total number of pregnancies of 65; 16 women had a total of 25 terminations of pregnancy; and 1 woman had a history of 4 therapeutic abortions. 53 women (76%) had started using contraception before the age of 20; 47% had used more than 1 type of contraception, 46% had used oral contraceptives only, 23% had used the condom, and 5% had used nothing. Age range at start of Depo Provera use was 14-40 years. The reasons given for commencing Depo-Provera included a combination of problems with other methods, forgetting OCs, and side effects of OCs. 47 (67%) had requested the use of Depo-Provera, of whom 13 (18%) had used it previously. 43 (61%) used Depo-Provera for 1 year or less, and only 1 patient had used it for 6 years. Among 52 women (74%) who had more than 1 dose of the injectable, the major side effects related to menstrual disturbances; 31 (41%) had amenorrhea. 2 of these women had breakthrough bleeding during the 1st dose. 17 women (24%) had either irregular bleeding or breakthrough bleeding, while 1 patient continued to have regular periods. 7 women (10%) had other side effects including depression; 4 women (6%) complained of weight gain; and 2 (3%) had breast soreness. 41 women (59%) were smokers, and 40% of them smoked 15 or more cigarettes per day. 35% of the women continued with the method beyond the study period, while the proportion of women within the clinic who continued using Depo-Provera was about 0.5%.
 ...
PMID:Depo Provera: a profile of current users. 214 Jun 75

The attempt is made to provide some answers on the use of Depo Provera. In the use of Depo Provera, the standard procedure is to give an injection of 150 mgs in 1 ml in an arm or hip muscle every 12 weeks, beginning soon after delivery or miscarriage or early in the menstrual cycle in the case of menstruating women. The outstanding attraction of the long-acting contraceptive injection in the minds of the 81,034 Chiang Mai acceptors is what can be described as the freedom from the fear of forgetting. The acceptors also enjoyed the ease and convenience of administration and the high effectiveness of the method. Of 142 women using this method for a year, on an average, only one woman will have an unexpected pregnancy. Depo Provera has a lower failure rate then IUDs, condoms, foams, jellies, or the "safe period," and it does not produce pelvic infection and inflammation wometimes seen with IUDs. It also does not effect breast milk in nursing mothers. The drawbacks to the use of the injectable contraceptive include amenorrhea, irregular menstrual periods, spotting, and sometimes heavy periods. Depo Provera also has other uses which include use in instances of threatened and habitual miscarriage and use in the treatment of endometriosis. Depo Provera is a safe method. Among the estimated 1 million or so users, there has not been a death caused by Depo Provera. Depo Provera has been approved for use in 10 European countries. The World Health Organization and the International Planned Parenthood Federation have approved the use of Depo Provera.
 ...
PMID:Extracts from the report on the Joint IGCC/IFRP East and South East Asia Seminar on Regional Fertility Research. 1217 3

If used correctly, only 2 out of every 100 women using a diaphragm would conceive over a year; however, because of forgetfulness the figure increases to 19 out of every 100. With good care they can last up to 12 years. The contraceptive sponge works because of the sperm-killing ingredients in the spermicide and because it blocks the cervix. The condom may also provide some protection against a variety of sexually transmitted diseases (STDs), such as herpes and gonorrhea. Missing one day of a low-dose oral contraceptive formulation (35 mcg) will have no consequences since the pill works by keeping hormone levels in the body elevated over time. With IUDs the only potential pitfall is forgetting to check for the tail every week of the first month and once a month thereafter to be sure the IUD is still in place. Some physicians suggest using a second form of contraception for the first three months after an IUD is inserted, since the odds are slightly higher it will be dislodged during this time. The manufacturers of Cu-7's and Cu-T's, as well as most physicians, recommend replacement of this device every three years. Experts are in agreement, however, that copper-containing IUDs carry a slightly lower risk of infection than Progestasert and the Lippes Loop. For postcoital contraception douching or using a spermicide within 10 minutes may help a bit. Although an IUD insertion can prevent pregnancy 90-95% of the time if it is done within five days of unprotected intercourse, because of the infection risk, this is not recommended unless a woman is planning on leaving the device in place as a contraceptive. The morning-after pill also works by preventing implantation of the fertilized egg. Taking two within 24 hours and two more 12 hours later prevents pregnancy 90-95% of the time, possibly with mild nausea or headache.
 ...
PMID:Birth-control trip-ups. How to avoid just-this-once risks. 1232 Feb 44

About 600 injections per year are administered in a Luxembourg family planning center using 3 types of long acting progestatives: Depo Provera 150 and 450 and Norigest. The method is no longer reserved for women with completed families and the mentally handicapped since its reversibility has been proven. Patients seeking this type of contraception must meet the same criteria as for oral contraceptives except that women with contraindications for estrogens may tolerate progestatives. Long acting progestatives offer the safety of minipills along with high effectiveness since the risk of forgetting a pill is removed. Some women with cardiac disease, diabetes, and circulatory problems are able to use injectables, but caution should be exercised with hypertensives and the obese because of possible weight gain. Women with coagulation problems or suspected fibromas should be excluded. Administered postpartum, pure progestatives do not affect lactation. Menstrual cycles are completely disturbed, with irregular and unpredictable bleeding until amenorrhea appears after 3-6 months. Women who are psychologically unable to accept amenorrhea should not use this method, as they are more likely to experience undesirable side effects. Return of fertility upon termination of use poses no problem and usually occurs after 6-10 months, even after a single injection. Treatment with a sequential contraceptive beginning on the day when the next injection would have been given may help to reestablish menstruation. The physician should determine through a preliminary interview the couple's psychological readiness for this type of contraception. A careful medical history and gynecological examination should be done to rule out contraindications, and treatment should begin in the 1st 3 days of the cycle. Irregular and prolonged bleeding after 6 months of use can be treated with oral administration of estrogen, or by proceeding to the next injection ahead of schedule. Administration of a mild diuretic is rarely necessary for water retention. Pregnancy during use of the method is very rare but usually occurs after the 2nd or 3rd treatment and may be detected only in the 3rd or 4th month. Uterine size should be assessed at each treatment for the 1st year. Short term local treatment with estrogen rapidly restores vaginal lubrication when necessary. No serious incidents have occurred with use of long acting progestatives at this clinic.
 ...
PMID:[Indications and medical survey of long acting progestatives used for contraception (author's transl)]. 1233 49